Skip to main content
Clinical Trials/NCT03745859
NCT03745859
Terminated
Not Applicable

Fraxinus- Assessment of an Open Source Virtual Bronchoscopic Navigation System

Norwegian University of Science and Technology1 site in 1 country4 target enrollmentNovember 19, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bronchial Neoplasms
Sponsor
Norwegian University of Science and Technology
Enrollment
4
Locations
1
Primary Endpoint
Evidence if the Fraxinus VBN System has a role in the assessment of peripheral pulmonary lesions
Status
Terminated
Last Updated
10 months ago

Overview

Brief Summary

To evaluate the feasibility of the Fraxinus Virtual Bronchoscope Navigation (VBN) System in the bronchoscopic access to target lesions. The study emphasizes the system´s efficacy in diagnostics of peripheral pulmonary lesions and the ease of use for the operator.

Detailed Description

Multi-center study. The study explores Fraxinus which is an open source, software only, simple guiding system for bronchoscopy. The system provides 3D maps with centerline-to-target information extracted from preoperative computed tomography. The ability of the system to guide a user to a peripheral target lesion will be evaluated. During bronchoscopy any established method for diagnostic sampling is allowed. User Evaluation will be essential to decide if the Fraxinus VBN System is beneficial in a clinical setting.

Registry
clinicaltrials.gov
Start Date
November 19, 2018
End Date
October 1, 2023
Last Updated
10 months ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • referred to thoracic department in any of the participating hospitals with undiagnosed peripheral pulmonary lesion(s) not visible by bronchoscopy
  • voluntary signed an informed consent

Exclusion Criteria

  • pregnancy
  • Any patient that the Investigator feels is not appropriate for this study for any reason

Outcomes

Primary Outcomes

Evidence if the Fraxinus VBN System has a role in the assessment of peripheral pulmonary lesions

Time Frame: 48 hours

The proportion of cases in which the use of the system is considered beneficial

Secondary Outcomes

  • Adverse events(48 hours)
  • Operators-reported satisfaction(48 hours)
  • Duration of procedure(48 hours)
  • Diagnostic yield(1 week)

Study Sites (1)

Loading locations...

Similar Trials